Selinexor plus COPL for newly diagnosed advanced NK/T lymphoma
Part of Cancer clinical trials.
This Phase 2 study tests whether a medicine called selinexor, combined with COPL, can shrink newly diagnosed NK/T-cell lymphoma that is advanced (stage III–IV). It also looks at how safely the treatment works in people who have good enough blood counts and organ function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 14 or older, and can be any sex
- Your NK/T-cell lymphoma has been newly diagnosed and confirmed by biopsy/pathology
- Your disease must have at least one measurable tumor spot (size rules)
- Your performance status is ECOG 0 to 2, meaning you’re able to do daily activities (with limited assistance for 1–2)
- You have advanced stage III to IV lymphoma, with an expected survival of more than 6 months
- Your blood, liver, and kidney tests are within required ranges (and fibrinogen is normal at the start of cycle 1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs—selinexor and azacitidine—given as a maintenance therapy after a donor stem cell transplant for NK/T-cell lymphoma. The goal is to help prevent the lymphoma from coming back.
This trial tests a new drug called selinexor combined with lower doses of radiation therapy for patients with a rare type of lymphoma (NK/T-cell lymphoma) that starts in the nose or upper throat. The goal is to improve how well the cancer responds to treatment while reducing radiation side effects.
This trial tests three drugs together—pomalidomide, an anti-PD-1 antibody, and selinexor—to treat primary central nervous system lymphoma (a blood cancer in the brain) that has returned after previous treatment. The goal is to see if this combination can shrink the cancer and help patients live longer.
This trial tests a combination of three drugs (selinexor, pegaspargase, and dexamethasone) for people with newly diagnosed NK/T-cell lymphoma. It aims to see if this treatment can shrink tumors and be safe.
This trial tests a combination of three drugs—selinexor, an anti-PD-1 antibody (immune therapy), and golidocitinib—for people with NK/T-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if this new combination can shrink tumors and help patients live longer.
This study tests a new combination of three drugs (selinexor, an anti-PD-1 antibody, and a chemotherapy regimen called P-GemOx) for people with NKT-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if this combination works better than current options.
Hear when a new NK T-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.